Cytyc Corp

Cytyc — Merger or Acquisition (June 2007)

49 slides from Cytyc's merger presentation, Jun 19, 2007

  1. Slide 1: A Leading Provider of Innovative Medical Technology

    A Leading Provider of Innovative Medical Technology

  2. Slide 2: Disclaimer Regarding Forward-Looking Statements

    Disclaimer Regarding Forward-Looking Statements Forward-Looking Statements Regarding Cytyc Investors are cautioned that statements in this presentation which are not strictly historical statements, including, without limitation, Cytyc's future financial condition, operating results and economic perf

  3. Slide 3: Disclaimer Regarding Forward-Looking Statements (continued)

    Disclaimer Regarding Forward-Looking Statements (continued) financial statements for the period 1996 through 2002, relating to certain employee stock option exercises, including the impact of the expected any regulatory review or litigation relating to such matters, the impact of new accounting requ

  4. Slide 4: Disclaimer Regarding Forward-Looking Statements (continued)

    Disclaimer Regarding Forward-Looking Statements (continued) Forward-Looking Statements Regarding the Proposed Hologic-Cytyc Transaction This presentation also includes forward-looking statements about the timing of the completion of the transaction, the anticipated benefits of the business combinati

  5. Slide 5: Disclaimer Regarding Forward-Looking Statements (continued)

    Disclaimer Regarding Forward-Looking Statements (continued) significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies, including third-p

  6. Slide 6: Important Information for Investors and Stockholders

    Important Information for Investors and Stockholders Hologic and Cytyc will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger. HOLOGIC AND CYTYC URGE INVESTORS AND STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OT

  7. Slide 7: Participants in the Solicitation

    Participants in the Solicitation Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic’s directors and executive officers and a description of their

  8. Slide 8: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS" and “EBITDA”. Adjusted EPS excludes the write-off and amortization of acquisition-related intang

  9. Slide 9: Growth Objectives and Strategy

    Growth Objectives and Strategy Growth Objectives and Strategy Deliver 20+% long-term earnings growth through: Global organic growth across divisions Internal research and development Strategic acquisitions and partnerships Grow existing businesses resulting in continued revenue growth and improved P

  10. Slide 10: Growth through Diversification

    1 Billion Growth through Diversification Growth through Diversification 2003 2005 2006 Diagnostic International Surgical $303 Millions $ $508 $608 10% 90% 61% 29% 10% 11% 34% 55% 73% 16% 11% 2004 $394

  11. Slide 11: Corporate Structure

    Corporate Structure Corporate Structure Domestic Surgical Products Division NovaSure ® Endometrial Ablation MammoSite ® Radiation Therapy Gliasite ® System Domestic Diagnostic Products Division ThinPrep ® Pap Test ThinPrep ® Imaging System Cellient ™ Automated Cell Block System Full Term ® : The Fet

  12. Slide 12: Surgical Products

    A Leading Provider of Innovative Medical Technology Surgical Products

  13. Slide 13: Domestic Surgical Products

    Domestic Surgical Products Domestic Surgical Products Changing medical practice with innovative medical technology NovaSure Endometrial Ablation • Treatment for excessive menstrual bleeding: $2.5 B market opportunity MammoSite Radiation Therapy • Treatment of early-stage breast cancer: $300 M opport

  14. Slide 14: NovaSure Procedure

    NovaSure Procedure NovaSure Procedure 4-minute, outpatient procedure No pretreatment drugs required Conscious sedation Recovery = 1 hour Highest success rates Reimbursement established nationwide

  15. Slide 15: Endometrial Ablation: A Large and Underserved Market

    Endometrial Ablation: A Large and Underserved Market Endometrial Ablation: A Large and Underserved Market Estimates per Cytyc Corporation *All age groups Hysterectomy, D&C, GEA Total Suffering Silent Sufferers Hormonal Therapy 7m 4.5m 1.8m 0.7m 1 in 5 women suffers from Abnormal Uterine Bleeding 2.5

  16. Slide 16: NovaSure's Competitive Advantage

    3.5 39.3 Lupron Yes 10-12 24 Lupron Single Yes 8 26.4 Lupron Double Yes 10 27.4 D&C Yes NovaSure’s Competitive Advantage 1.4 4.2 None No NovaSure RadioFrequency Microsulis Microwave AMS Her Option Cryotherapy BSC HTA Hot water J&J Therma Choice Hot water Treatment Time* Procedure Time* Pre-Treatment

  17. Slide 17: Favorable Reimbursement: 2007

    Favorable Reimbursement: 2007 Favorable Reimbursement: 2007 CPT Code 58563: Endometrial Ablation ~ $1,185 $336 ~ $1,090 Margin ~ $1,000 ~ $1,000 Product cost $2,185 $336 $2,090 Reimbursement M.D. Institution M.D. Office Outpatient Hospital (Illustrative)

  18. Slide 18: GEA Market Opportunity

    GEA Market Opportunity 2006 NovaSure Market Share and Total Procedure Potential GEA Market Opportunity 2006 NovaSure Market Share and Total Procedure Potential NS Share = 62%* NS Share = 9% NS Share = 3% * Note:US NovaSure dollar share equals 69% 1,000,000 2,000,000 3,000,000 4,000,000 5,000,000 6,0

  19. Slide 19: MammoSite Radiation Therapy

    MammoSite Radiation Therapy MammoSite Radiation Therapy Creating new standard of care Deliver optimal dose of radiation to tissue at highest risk of cancer recurrence Minimize damage to healthy tissue Expanding data supports partial breast radiation and MammoSite Clinical trial (5-year data; 43 pati

  20. Slide 20: MammoSite Procedure

    MammoSite Procedure MammoSite Procedure STEP 1: After tumor removal, uninflated balloon placed in the tumor resection cavity STEP 2: Fill balloon with saline solution to create a symmetric sphere Allows for calculation of the radiation treatment STEP 3: Deliver radiation by placing a radioactive see

  21. Slide 21: MammoSite Market Opportunity

    50,000 100,000 150,000 200,000 250,000 300,000 MammoSite Market Opportunity 275,221 189,490 131,695 126,002 MammoSite Primary U.S. Cases of Breast Cancer and DCIS (.4% Incidence, 40+) Patients Eligible for Breast Conserving Therapy (Excludes >3cm, Size A) Patients Receiving Breast Conserving Therapy

  22. Slide 22: MammoSite Reimbursement: 2007

    MammoSite Reimbursement: 2007 MammoSite Reimbursement: 2007 5-6 days 30-35 days Treatment Time $12,660 $10,545 Professional Fee: Free- standing Center (radiation oncologist) $ 1,705 $ 2,565 Professional Fee Hospital (radiation oncologist) $12,445 $ 8,725 Hospital Facility Fee MammoSite Radiation Who

  23. Slide 23: Hysteroscopic Sterilization -- Adiana

    Hysteroscopic Sterilization -- Adiana Hysteroscopic Sterilization -- Adiana Alternative to tubal ligation Radiofrequency generator One-time-use delivery catheter FDA process underway Complementary to NovaSure Endometrial Ablation System $1 billion U.S. market opportunity Reimbursement established

  24. Slide 24: Cytyc Surgical Products - Summary

    Cytyc Surgical Products - Summary Cytyc Surgical Products - Summary Changing medical practice with products that address potential US markets > $5B NovaSure best-in-class product addressing a $2.5B market NovaSure Elective use > $1B MammoSite creating a new standard of care with $300MM US opportunit

  25. Slide 25: Diagnostic Products

    A Leading Provider of Innovative Medical Technology Diagnostic Products

  26. Slide 26: Domestic Diagnostic Products

    Domestic Diagnostic Products Domestic Diagnostic Products ThinPrep ® Pap Test ThinPrep ® Imaging System FullTerm ® : The Fetal Fibronectin Test Cellient ™ Automated Cell Block System

  27. Slide 27: ThinPrep System Advantages

    Since ThinPrep introduction in 1996, estimated number of cervical cancer cases in the US decreased 28% ThinPrep System Advantages ThinPrep System Advantages Superiority to Conventional Pap ThinPrep Imaging System ThinPrep Pap Test Market Share (%) Estimated New Cases (1,000) HPV FDA approved CT/NG F

  28. Slide 28: ThinPrep Imaging System

    ThinPrep Imaging System ThinPrep Imaging System Advanced computerized imaging Dual screening approach Improves accuracy Improves lab economics Increases reimbursement Decreases labor costs Improves workflow Protects ThinPrep market share Significant increase in HSIL

  29. Slide 29: ThinPrep Economic Advantage

    ThinPrep Economic Advantage ~$8.00 ~$20.00 $12.00 $ 3.70 Profit ~$1.00 ~$17.00 $16.00 $11.00 Total Cost 5-6 5-6 0.00 0.00 Imaging Fee 0.00 7.00 7.00 2.00 Supplies, etc. (4.50) 4.50 9.00 9.00 Manual Review Costs $9.00 $37.00 $28.00 $14.70 Reimbursement TIS TPPT CP Illustrative

  30. Slide 30: ThinPrep Imaging System: Becoming the Standard of Care

    ThinPrep Imaging System: Becoming the Standard of Care ThinPrep Imaging System: Becoming the Standard of Care Notes: Imaging started in Q2 of 2003 Percent Slides Imaged 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% Q4 2003 Q4 2004 Q4 2005 Q4 2006 1% 13% 30% 40%

  31. Slide 31: Cellient Automated Cell Block System

    Cellient ™ Automated Cell Block System Cellient ™ Automated Cell Block System Allows individual cells or small tissue samples (<2mm diameter) to be processed for histological examination Eliminates operator dependence Provides standardized, consistent preparations in less than one hour, and ensures

  32. Slide 32: FullTerm: The Fetal Fibronectin Test

    Full Term: The Fetal Fibronectin Test Full Term: The Fetal Fibronectin Test Identifies women at risk of preterm birth FDA approved Reimbursement established Market opportunity: $500 million worldwide

  33. Slide 33: Gestiva

    Gestiva Gestiva Drug candidate for prevension of preterm birth Orphan drug status Approvable letter October 2006 Market opportunity: $100 million worldwide

  34. Slide 34: International

    A Leading Provider of Innovative Medical Technology International

  35. Slide 35: Cytyc International – Driving Growth Worldwide

    Operating in over 20 countries Marlborough Cytyc International – Driving Growth Worldwide Legend Australia UK Iberia France Italy Germany Switzerland Hong Kong Costa Rica China Mexico Brazil South Africa So. Korea Company presence Key distributors Japan Canada

  36. Slide 36: International Revenue 2004 – 2006

    International Revenue 2004 – 2006 International Revenue 2004 – 2006 10000 20000 30000 40000 50000 60000 70000 80000 2004 2005 2006 ROW AsiaPac Europe Total CAGR 30% $40m $52m $68m

  37. Slide 37: Global ThinPrep Market Opportunity

    Less than 10% market penetration worldwide Europe Asia - Pacific Rest of World Total: $500+ million annual revenue opportunity Additional upside from Imager Tests (Millions) Global ThinPrep Market Opportunity Global ThinPrep Market Opportunity

  38. Slide 38: Large Market Opportunity for NovaSure

    Less than 5% market penetration world wide $130+ million annual revenue opportunity EA Procedures (Thousands) Large Market Opportunity for Large Market Opportunity for NovaSure NovaSure Europe Asia - Pacific Rest of World Total:

  39. Slide 39: Cytyc International Summary

    Cytyc International Summary Cytyc International Summary Pursue 3 key growth levers Capture and solidify diagnostic share Expand Gyn surgery share and market size Lay foundation for MammoSite growth Strengthen our infrastructure to better serve customers and capture market opportunities

  40. Slide 40: Creating a Global Leader in Women's Healthcare

    Creating a Global Leader in Women’s Healthcare Continuing a legacy of leading technology, innovation and rapid growth May 21, 2007

  41. Slide 41: Strategic Rationale Combined Strengths

    Strategic Rationale Combined Strengths Expanded Product Portfolio Comprehensive Sales Coverage Ability to Leverage OB/GYN Channel Significant Cross-Selling Synergies Enhanced International Presence Creating a Global Leader in Women’s Healthcare Market Share Leader in Major Product Lines Proven Manag

  42. Slide 42: Comprehensive Women's Healthcare Platform

    MultiCare Stereotactic Biopsy Discovery Osteoporosis Screening Selenia Breast Cancer Screening MammoSite Radiation Therapy ThinPrep Pap Test & Imaging System Cervical Cancer Screening NovaSure Endometrial Ablation Adiana Contraception FullTerm - Adeza Preterm Labor Best-in-Class Solutions in Women’s

  43. Slide 43: Solutions for Major Women's Healthcare Issues

    Solutions for Major Women’s Healthcare Issues Helica Unpenetrated 1 in 3 Gestiva International ThinPrep Imaging System International Tomosynthesis Suros Celero Additional Opportunities Adiana FullTerm Fetal Fibronectin Discovery Sahara NovaSure ThinPrep Pap Test Selenia MultiCare Suros ATEC MammoSit

  44. Slide 44: Transaction Overview

    Permanent financing anticipated to be combination of pre-payable term loan and equity-linked securities Financing: Hologic, Inc. (NASDAQ: HOLX), continue Cytyc name Name of NewCo: Third Quarter of CY2007 Timing to Close: Shareholders of both companies, customary closing conditions and HSR anti-trust

  45. Slide 45: Financial Rationale

    Multiple platforms to enhance top and bottom line growth Increased scale through diversification of revenue and strong margin profile Enhanced cash flow; LQA EBITDA of ~$436M Revenue and cost synergy opportunities Estimated more than $0.10 accretive to adjusted EPS within the first full year after c

  46. Slide 46: Combined Financial Strength

    Combined Financial Strength 46% Gross Margin $161M EBITDA $724M Revenue LQA Hologic 75% Gross Margin $275M EBITDA $720M Revenue LQA Cytyc 60% Gross Margin $436M EBITDA $1.44B Revenue LQA Combined Company

  47. Slide 47: FY2008 Guidance and Long Term Outlook

    FY2008 Guidance and Long Term Outlook 2008 Guidance Revenue: In excess of $1.70B Adjusted EPS : $2.35-2.40 / share Gross margin: 65% Long-Term Outlook Revenue Growth: 20% Adjusted EPS Growth: 20%+ Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets, and rela

  48. Slide 48: Creating a Global Leader in Women's Healthcare

    Creating a Global Leader in Women’s Healthcare Comprehensive Women’s Healthcare Product Portfolio – Complementary best-in-class technologies Expanded Commercial Capabilities – Expansive U.S. sales channel coverage – Enhanced presence in key international markets – Platform for entry into new markets

  49. Slide 49: A Leading Provider of Innovative Medical Technology

    A Leading Provider of Innovative Medical Technology

Cytyc — Merger or Acquisition (June 2007) on 6ix